Literature DB >> 2501669

A mutation causing reduced biological activity and stability of thyroxine-binding globulin probably as a result of abnormal glycosylation of the molecule.

Y Mori1, S Seino, K Takeda, I L Flink, Y Murata, G I Bell, S Refetoff.   

Abstract

T4-binding globulin (TBG), a 54-kilodalton glycoprotein, is the major thyroid hormone transport protein in man. The exact nature of the mutations causing X chromosome-linked TBG deficiency, which affect about 1 in 2,500 newborn males, is unknown. Here we report the sequence of a unique variant TBG (TBG-Gary) encoding a protein with severely impaired T4 binding as well as decreased stability at 37 C, resulting in its rapid in vivo denaturation. A single nucleotide substitution in the codon for residue 96 of the mature protein replaces isoleucine with asparagine; this replacement creates an additional site for N-linked glycosylation. The anodal shift of TBG-Gary on isoelectric focusing gel electrophoresis suggests that this new site is likely glycosylated. Since glycosylated is required for TBG to assume its correct tertiary structure, but is not subsequently necessary for maintenance of the biological properties or stability of the molecule, we believe that the likely presence of additional carbohydrate probably affects a higher order structure of the molecule and is thus responsible for the reduced stability and hormone binding activity of TBG-Gary (TBGASN-96).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501669     DOI: 10.1210/mend-3-3-575

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  14 in total

1.  Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.

Authors:  P R Elliott; X Y Pei; T R Dafforn; D A Lomas
Journal:  Protein Sci       Date:  2000-07       Impact factor: 6.725

Review 2.  TBG deficiency: description of two novel mutations associated with complete TBG deficiency and review of the literature.

Authors:  Deborah Mannavola; Guia Vannucchi; Laura Fugazzola; Valentina Cirello; Irene Campi; Giorgio Radetti; Luca Persani; Samuel Refetoff; Paolo Beck-Peccoz
Journal:  J Mol Med (Berl)       Date:  2006-09-01       Impact factor: 4.599

3.  Sequence of the variant thyroxine-binding globulin (TBG) in a Montreal family with partial TBG deficiency.

Authors:  O E Janssen; K Takeda; S Refetoff
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

Review 4.  Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations.

Authors:  M S Mimoto; S Refetoff
Journal:  J Endocrinol Invest       Date:  2019-07-27       Impact factor: 4.256

5.  Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.

Authors:  R B Parad; J Kramer; R C Strunk; F S Rosen; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Molecular basis for the properties of the thyroxine-binding globulin-slow variant in American blacks.

Authors:  M R Waltz; T N Pullman; K Takeda; P Sobieszczyk; S Refetoff
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

7.  A Novel Mutation in the TBG Gene Producing Partial Thyroxine-Binding Globulin Deficiency (Glencoe) Identified in 2 Families.

Authors:  Theodora Pappa; Lars C Moeller; Deborah V Edidin; Silvana Pannain; Samuel Refetoff
Journal:  Eur Thyroid J       Date:  2017-02-02

Review 8.  Studies on thyroxine-binding globulin.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

9.  Precise localization of the human thyroxine-binding globulin gene to chromosome Xq22.2 by fluorescence in situ hybridization.

Authors:  Y Mori; Y Miura; Y Oiso; S Hisao; K Takazumi
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

Review 10.  Inherited defects of thyroxine-binding proteins.

Authors:  Theodora Pappa; Alfonso Massimiliano Ferrara; Samuel Refetoff
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-09-30       Impact factor: 4.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.